BRILINTA Granted FDA Priority Review for the Reduction of Subsequent Stroke in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack
AstraZeneca today announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for BRILINTA for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack. The Prescription Drug User Fee Act date, the FDA action date for this...
AstraZeneca Plc (AZN.L) Announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack (TIA). #AZN
RNS Number: 5186 S AstraZeneca PLC 09 July 2020 9 July 2020 07:00 BST. Brilinta granted FDA Priority Review for the reduction of subsequent stroke in patients who had an acute ischemic stroke or transient ischemic attack. Brilinta in combination with aspirin could be the first FDA-approved dual antiplatelet therapy to reduce the rate of stroke in these...
AstraZeneca Plc (AZN.L) Announced that Lynparza (olaparib) has been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The approval by the European Commission was based on results from the Phase III POLO trial.v #AZN
RNS Number: 3706 S AstraZeneca PLC 08 July 2020 8 July 2020 07:00 BST. Lynparza approved in the EU for BRCA- mutated metastatic pancreatic cancer. AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved in the European Union for patients with germline BRCA-mutated metastatic pancreatic cancer.
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6. 1. As at 30 June 2020 the issued share capital of AstraZeneca PLC with voting rights is 1,312,271,081 ordinary shares of US $0.25. The above figure for the total number of voting rights may be used by shareholders as the denominator...
RNS Number: 5565 R AstraZeneca PLC 30 June 2020 30 June 2020 15:00 BST. AstraZeneca PLC announces that, on 29 June 2020, it was notified by Pascal Soriot, Chief Executive Officer, that, on 29 June 2020, Mr Soriot ceased to be beneficially interested in 127,389 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil...
AstraZeneca Plc (AZN.L) Announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease. Selumetinib is co- developed and co-commercialised with MSD Inc., Kenilworth, N.J., US. #AZN
PT010 Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial
Full results from the positive Phase III ETHOS trial showed AstraZeneca’ s triple-combination therapy PT010 demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease.
RNS Number: 2547 Q AstraZeneca PLC 17 June 2020. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2539 Q AstraZeneca PLC 17 June 2020. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
AstraZeneca to supply Europe with up to 400 million. AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance, spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's COVID-19 vaccine, with deliveries starting by the end of 2020.. The IVA is committed to providing...
AstraZeneca Plc (AZN.L) Announced that Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme has been approved by the Financial Conduct Authority and is available for viewing. The last drawdown under the EMTN programme was in 2016. #AZN
AstraZeneca to Showcase Leadership in Treating Type 2 Diabetes and Cardiorenal Complications at ADA 2020
AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80 th American Diabetes Association Virtual Scientific Sessions, June 12– 16 2020. The data are among 23 accepted abstracts, including four oral presentations, covering trials that showcase the depth and breadth of potential cardio, renal and...
RNS Number: 6000 P AstraZeneca PLC 11 June 2020 11 June 2020 07:00 BST. Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme.. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration
Accent Therapeutics and AstraZeneca will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer. The collaboration combines Accent’ s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’ s...
|Net Interest Income|
|Consolidated Net Income|
|Interest Income after Loan Loss Provision|
|Operating Income (EBIT)|
|Operating profit per share|
|EPS (Diluted - Before Unusual Expense)|
|EPS (Fully Diluted)|
Balance Sheet - Assets
|Net Property, Plant & Equipment|
|Cash & Short Term Investments|
|Other Financial Assets|
|Total Short Term Accounts Receivable|
|Total Accounts Receivable|
|Total Cash & Due from Banks|
|Premium Balance Receivables|
|Total Current Assets|
|Tangible Other Assets|
|Other Intangible Assets|
Balance Sheet - Liabilities
|Liabilities & Stockholders' Equity|
|Other Current Liabilities|
|Total Current Liabilities|
|Provision for Risks & Charges|
|Losses, Claims & Reserves|
Balance Sheet - Other
|Dividends Per Share (Gross)|
|Dividends Per Share|
|Dividends Per Share (1-yr Annual Growth)|
|Dividend payout per share|
|Common Shares Outstanding|
|Common Shares (EPS Basic)|
|Common Shares (EPS Diluted)|
|Closely Held Shares|
|Total Shareholders' Equity|
|Net Interest Margin|
|Gross Profit Margin|
|Debt / EBITDA|
|Total Debt / Assets|
|Assets Per Employee|
|Common Stock Par / Carry Value|
|Dividend Yield - Security|
|Cash Dividend Coverage Ratio|
|Exchange Rate Effect|
|Net Change in Cash|
|Income Tax Payable|
|Cash Dividends Paid|
|Long Term Debt|
|Short Term Debt|
|Operating Income After Interest Expense|
|Operating Income Before Interest Expense|
|Purchase / Sale of Investments|
|Other Appropriated Reserves|